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DSM-IV (TR)Abstract Background: Autism spectrum disorders (ASDs) are a group of neurodevelopmental
disorders characterized by pervasive abnormalities in social interaction and communication, and
repetitive and restricted behavioral patterns and interests. ASD include autistic disorder, Asperger’s
disorder, pervasive developmental disorder not otherwise speciﬁc and childhood disintegrative dis-
orders.
Objectives: To detect plasma level of transforming growth factor beta 1 (TGFbl) in children with
ASD and to ﬁnd out correlation between the plasma level of TGFb1 and severity of ASD.
Patients and methods: Our study included 30 patients with autistic spectrum disorder (ASD) diag-
nosed on the basis of criteria of autistic spectrum disorders as deﬁned in Diagnostic and Statistical
Manual of Mental Disorders fourth edition text revised (DSM-IV) (TR). They were 26 males and 4
females, their ages ranged from 3 years to 13 years. Thirty apparently healthy sex and age matched
children served as controls (22 males and 8 females). They were subjected to full history taking, clin-
ical examination and severity rating using Child Autistic Rating Scale of Children (CARS) and
Diagnostic and Statistical Manual of Mental Disorders fourth edition text revised (DSM-IV) (TR).
Results: Our study revealed: (a) sex distribution among the patient group with male/female ratio
6.5:1; (b) mean value of maternal age was signiﬁcantly higher among patients than controls; (c) about
50% of patients had a history of prenatal complication; (d) the patient group shows lower plasma
level of TGFb1 compared to the control group.
Conclusion: There may be an important role for the immune system in autism spectrum disorders
that may have profound implications for diagnosis and treatment of this disorder. A negative corre-
lation was found between severities of ASD and TGFb1 plasma level.
ª 2014 Egyptian Society of Ear, Nose, Throat and Allied Sciences. Production and hosting by Elsevier
B.V. All rights reserved.ed.
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Autistic spectrum disorder is a complex developmental disor-
der with social and communication dysfunction at its core.
Autistic spectrum disorders are a wide spectrum of conditions
having a common triad of impairments. Deﬁcits include those
in social communication, social interaction and social imagina-
tion. It ﬁrst gives signs during early childhood. Impairments
result from maturation-related changes in various systems of
the brain.1
The prevalence of ASD has increased substantially over the
last decade rising from 5 to 60/10,000.2 The male to female
ratio is three or four to one, but when it occurs in females it
is more severe.3 The exact etiology of autism and ASD
remains unknown, it is likely to result from a complex combi-
nation of environmental, immunological and genetic factors.
Strong genetic links have been shown for cases with Tuberous
sclerosis, Fragile X, neuroﬁbromatosis, and chromosomal
abnormalities.4,5
There is growing awareness of an immunological involve-
ment in children with ASD. Evidence of immune dysregulation
has been observed in some individuals with ASD including
increase levels of pro-inﬂammatory cytokines in brain tissue,
CSF and plasma and increased production of pro-inﬂamma-
tory cytokines by peripheral blood mononuclear cell culture
when compared to typically developing control.6–8 The regula-
tory immune response is also critical in the down-regulation of
the inﬂammatory immune response following infection, thus
limiting potential tissue damage. Immunosuppressive cyto-
kines such as transforming growth factor beta 1 (TGFb1)
are critical for immune homeostasis, important in induction
of unresponsiveness in activated T cell.9,10
There are several studies that demonstrate an alteration or
dysregulation of immune response in autism compared with
matched controls.7,11–13 Altered TGFb1 levels have been
observed in brain specimens of subjects with autism.8 Another
study revealed decreased plasma TGFb1 in adults with
autism.14
This work was designed to evaluate patients with autistic
disorders through detailed history and rating their severity
using CARS, together with detection of the plasma level of
TGFb1, in order to ﬁnd out if it is altered in ASD thus it
can help in understanding the nature of the problem and it
may be used as an early marker in diagnosis.2. Subjects and methods
2.1. Subjects
The study sample was composed of 30 children suffering from
autism spectrum disorders (ASDs), attending outpatient clinic
of Pediatric Neuropsychiatry and Phoniatrics of Tanta Univer-
sity Hospital.
2.2. Inclusion criteria
1- Age range of 3–13 years.
2- Children diagnosed by using Diagnostic and Statistical
Manual of Mental Disorders fourth edition text revised(DSM-IV) (TR) and Child Autistic Rating Scale of Chil-
dren (CARS).2.3. Exclusion criteria
1- Other mental or neurobehavioral disorders.
2- Chronic diseases or infections.
3- Medications modulating immunity.
4- Immune deﬁciency states.
The control group was composed of 30 clinically healthy
properly matched children (22 males and 8 females), their ages
ranged from 3 to 13 years. None of them had a history of
chronic illness. Their total score fell in the range of 15–29
according to CARS.
2.4. Ethical issues
A formal written consent of parents or guardians was taken
separately after explanation and assurance that the procedure
will not harm patient or delay his improvement.
All participants’ names were hidden and replaced by code
number to maintain privacy of the participant.
2.5. Methods
All children in this study were subjected to the following:
1- Full history taking especially developmental history and
prenatal complications.
2- Physical examination and especially neurological
examination.
3- Cognitive age (mental age) using Stanford Bine intelli-
gence scale (1960) or the non-verbal intelligence test of
Snijder Oomen (1979) to exclude other mental or neuro-
behavioral disorders.15
4- Psychometric study using:
 Diagnostic and Statistical Manual of Mental Disor-
ders fourth edition text revised (DSM-IV) (TR).1
 Child Autistic Rating Scale (CARS).16
5- Laboratory detection of plasma level of transforming
growth factor beta 1 (TGFb1) by ELISA.13
2.6. Child Autistic Rating Scale (CARS)
The child is considered non-autistic when his/her total score
falls in the range of 15–29, mildly–moderately autistic when
the total score falls in the range of 30–36 and severely autistic
when the total score falls in the range of 36–60.
2.7. Monitoring of the data
Data were recalled in a conﬁdential manner and the privacy of
all patients was maintained.
2.8. Duration of the study
The study duration was 15 months.
Table 3 Correlation between plasma level of TGFb1 and
CARS, age, weight, length, HC, and mother’s age.
Correlations
Item TGF
R P-value
CARS 0.574 0.001*
Age 0.041 0.828
Weight 0.136 0.472
Length 0.014 0.944
HC 0.036 0.849
Mother’s age 0.242 0.198
Non-signiﬁcant = P> 0.05.
* Signiﬁcant = P< 0.05.
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 Detection of plasma level of TGF b1 in children suffering
from ASD.
 Finding out a correlation between plasma level of TGF b1
and severity of ASD.
2.10. Statistical design
Statistical analysis in the present study was conducted, using
SPSS-V17. Descriptive statistics, Student’s t-test, and Linear
Correlation Coefﬁcient tests were used in analyzing the data
of the study.
3. Results
The present study showed 24 mildly-moderately autistic with
total score falls in the range of 30–36 and 6 severely autistic
with total score falls in the range of 36–60 according to CARS.
Fifteen of patients had a history of prenatal complications
such as maternal prenatal medication use (3 cases), bleeding
(one case), gestational diabetes (2 cases), previous fetal loss
(3 cases) and maternal hypertension (2 cases), proteinuria
(one case), pre-eclampsia and swelling (3 cases).
Table 1 shows maternal age of patient group range (23–
39 years) with a mean 29.33 ± 4.67 which is higher than the
maternal age of control group range (22–25 years) with a mean
23 ± 1.03. The comparison in-between showed statistical sig-
niﬁcance at P value <0.05.
Table 2 shows a comparison between patient and control
group regarding plasma level of TGFb1 and showed a signiﬁ-
cant difference between the two groups where P value <0.05.
Table 3 shows a correlation between plasma level of TGFb1
and CARS, age, weight, length, head circumference (HC) andTable 1 Comparison between patient and control as regards
maternal age at conception.
Groups Mother’s age (years) t-Test
Range Mean ± SD t P-value
Patients 23.00–39.00 29.333 ± 4.611 6.644 <0.001*
Controls 22.000–25.000 23.600 ± 1.037
Non-signiﬁcant = P> 0.05.
* Signiﬁcant = P< 0.05.
Table 2 Comparison between patient and control as regards
plasma level of TGFb1.
Groups TGFb1 (ng/ml) t-Test
Range Mean ± SD t P-value
Patients 2.000–30.000 15.667 ± 8.691 2.162 0.035*
Controls 15.000–30.000 20.200 ± 4.137
Non-signiﬁcant = P> 0.05.
* Signiﬁcant = P< 0.05.mother’s age. The comparison between the two groups showed
a signiﬁcant difference only regarding CARS (P value <0.05).
4. Discussion
Autism Spectrum Disorders (ASDs) are neurodevelopmental
diseases characterized by restricted interests, repetitive behav-
iors, and deﬁcient language and social skills.17 While there
are no concrete biological markers for the disorder, immune
anomalies are frequently described among individuals with
ASD and their family members.18,19
Immunological anomalies involving cytokines, immuno-
globulins, inﬂammation, and cellular activation have been
noted in individuals with autism.20 Cytokines are secreted pro-
teins that control the intensity, duration, and character of an
immune response. Cytokines also interact with neural systems,
and are involved in neural development and maintenance.21
Transforming growth factor beta (TGFb) has been linked
to ASD in multiple studies.6,8,14 TGFb is involved in diverse
aspects of development, cell migration, apoptosis, and regula-
tion in both the immune system and central nervous system
(CNS).22,23
Our study was conducted on 30 autistic children and 30
controls, their age ranged from 3 to 13 years with average
age 5.95 years. In the current study 86.67% of patients were
male and 13.33% were female in a ratio 6.5:1. These ﬁndings
are in agreement with other studies that ensure that males
are predominantly affected with autism than females. Webb
et al.24 in the UK found that the male:female ratio was 6.5:1;
Fombonne et al.25 found that the M/F ratio was 5:1 similar
to Lazoff et al.26 in Canada.
The mean maternal age at the time of conception was
29.33 ± 4.61 years in a group of patients. These ﬁndings are
in accordance with a large number of studies which reported
an association of ASD with advanced maternal age.27–29 Later
on El-Baz et al.30 in their study about ASDs in Arab countries
recruited a total of 37 boys and 23 girls from three Arab coun-
tries (Egypt, Saudi Arabia, Jordan). High maternal age
(mother, >35 years) at birth was found in 23% of autistic
children.
The present study showed that 50% of the patient group
has a history of prenatal complication. Such ﬁndings go hand
in hand with the work of Glasson et al.31 who showed that
fetal/infant characteristics such as low APGAR scores, breech
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Also, El-baz et al.30 found that postnatal factors such as his-
tory of hypoxia, resuscitation and history of jaundice were
considered signiﬁcant risk factors for autism.
We examined the regulatory cytokine transforming growth
factor beta 1 (TGFb1) because of its role in controlling
immune responses8. Plasma levels of active TGFb1 were eval-
uated in 30 children with ASD compared with 30 controls.
Children with ASD had signiﬁcantly lower plasma TGFb1 lev-
els (15.67 ± 8.69) compared with typically developing controls
with the mean of 20.2 3:4.1 ng/ml with P value =0.035. This is
in agreement with previous researchers. Vargas et al.6 observed
altered TGFb1 levels in brain specimens of subjects with aut-
ism; Okada et al.14 showed in adult patients with ASD that
the serum levels of TGFb1 were signiﬁcantly lower than those
of normal controls. Ashwood et al.8 found that plasma levels
were signiﬁcantly lower in children with ASD compared with
typically developing general population controls.
Moreover, several studies have shown peripheral immune
abnormalities in patients with autism including abnormal or
skewed T helper cell cytokine proﬁles, decreased lymphocyte
numbers, decreased T cell mitogen response, and an imbalance
of serum immunoglobulin levels.7
The administration of anti-inﬂammatory cytokines as
TGFb1 or anti-inﬂammatory medications, such as the thiazo-
lidinedione pioglitazone (unless contra-indicated) or hista-
mine-receptor blockers to the pregnant mother alleviates
depression and reduces the risk of developing an autistic
child.32 Also the treatment of autistic children with the anti-
inﬂammatory medication pioglitazone, a nonsteroidal anti-
inﬂammatory drug (NSAID) of the thiazolidinedione class,
improved autistic symptoms through reducing the activation
of microglia and subsequent neuroinﬂammation.33
There was a negative correlation between the level of
TGFb1 and CARS which is a diagnostic tool for autism and
reﬂects the severity of autism in the current study. The lower
the level of TGFb1 the higher the score with CARS which indi-
cates more severity. Such ﬁndings were in agreement with Ash-
wood et al.8 who found that decreasing levels of TGFb1 in
plasma correlated with worse behavioral scores on the ABC
(aberrant behavior checklist).
The data suggest that immune responses in autism may be
inappropriately regulated due to reductions in TGFb1. Such
immune dysregulation may predispose to the development of
the symptoms and behaviors that are associated with ASD.
From the previous data we may conclude that proper
exploration of immunological features in autism presents an
exciting opportunity to tease apart the biology of disorder,
and may lead to therapeutic interventions.5. Conclusion
Based on the results of this study, it could be concluded that:
 There is reduction in TGFb1 level in plasma of children
who have ASD.
 There is a negative correlation between TGFb1 plasma level
and the severity of the disease; the lower the level of
TGFb1, the higher the scores of CARS indicating more
severity.Recommendations
From this study we can recommend the use of TGFb1 as a
serological marker in children who have recently been diag-
nosed with ASD as well as its use as a biological marker to
monitor the efﬁcacy of therapy.
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